Please login to the form below

Not currently logged in
Email:
Password:

Chris Bowden joins Agios

He is former VP, product development oncology at Genentech
Agios Chris Bowden

Agios Pharma has named former Genentech VP Chris Bowden as chief medical officer.

Bowden spent eight years at Genentech as VP, product development for its oncology unit. During this time he worked on major cancer medicines, such as melanoma drug Zelboraf (vemurafenib) and Erivedge (vismodegib) for patients with unresectable, locally advanced or metastatic basal cell carcinoma.

Both drugs are now marketed by Roche since its takeover of Genentech in 2009.

Bowden's knowledge of oncology will benefit Agios as it prepares to advance the development of three candidates focused on cancer and inborn errors of metabolism.

“Agios is leading the investigation of precision medicine in the field of cellular metabolism, and has rapidly advanced several promising oral medicines to treat a range of serious diseases,” said Bowden.

Prior to working for Genentech Bowden spent three years as executive director for EMEA for Bristol-Myers Squibb. His earlier industry career includes spells as Janssen and Pharmacia.

15th May 2014

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Iguazu

Iguazu Ltd is a digital healthcare agency, delivering tactical and innovative solutions. WHAT WE DO We are Closed Loop Marketing...

Latest intelligence

Sharing patient stories for World Pulmonary Hypertension Day
For World Pulmonary Hypertension Day and we’re here to help raise awareness of pulmonary hypertension (PH) - a frequently under and misdiagnosed condition. Created in collaboration with the PH patient...
How nature can help you manage the pressures of agency life
Paul Hutchings, founder of fox&cat, outlines how nature can help you can boost staff wellbeing in your agency this Mental Health Awareness Week...
How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...